2014 northwest melanoma symposium slide deck
DESCRIPTION
On April 5, 2014 the MRF partnered with Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center to provide a free educational event dedicated to melanoma patients and the people who support them.TRANSCRIPT
![Page 1: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/1.jpg)
Welcome to the 2014 Melanoma Symposium* 8:30 am – 8:40 am Introduction Dr. David Byrd 8:40 am – 9:40 am Familial Melanoma & Genetic Predisposition Dr. Sancy Leachman Predisposition 9:40 am – 10:10 am Intra-tumoral Immunotherapy of Dr. Shailender Bhatia Melanoma: What happens in there, does not always stay there! 10:10 am – 10:25 am Morning Break 10:25 am – 10:55 am Radiotherapy and Immune Therapy: Dr. Upendra Parvathaneni An alliance for the future 10:55 am – 11:30 am Questions & Answers with Morning Presenters 11:30 am – 12:30 pm Lunch and Networking 12:30 pm – 1:00 pm Precision Medicine Dr. David Byrd 1:00 pm – 2:45 pm Patient Panel 2:45 pm – 3:15 pm Afternoon Break – Enjoy smoothie samples from SCCA Nutrition 3:15 pm – 3:45 pm Getting Involved Dr. Tim Turnham 3:45 pm – 4:00 pm Closing Remarks Dr. David Byrd Dr. Kim Margolin
*Speakers/presentations are being filmed. Video will be available online at www.SCCAblog.org.
![Page 2: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/2.jpg)
Welcome & Introduction
Thank You to Fred Hutchinson Cancer Research Center
![Page 3: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/3.jpg)
Familial Melanoma & Genetic Predisposition
Sancy Leachman, MD, PhD – Keynote Speaker Chair of the Department of Dermatology
Director of the Knight Cancer Institute Melanoma Program Oregon Health and Science University
![Page 4: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/4.jpg)
Familial Melanoma & Genetic Predisposition
Sancy Leachman, MD PhD Oregon Health & Science University
![Page 5: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/5.jpg)
Disclosures
• Myriad Genetics
![Page 6: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/6.jpg)
Overview
• When is genetic testing helpful?
• Available genetic tests for melanoma
• Current state of DTC genetic testing
![Page 7: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/7.jpg)
What Is Familial Melanoma?
Hansen et al, Lancet Oncol., 2004
![Page 8: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/8.jpg)
Hereditary Melanoma: An autosomal dominant cutaneous cancer syndrome
Pancreatic
Melanoma
Pancreatic & Melanoma
![Page 9: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/9.jpg)
Background: Inheritance of Melanoma Risk Is Complex
Population Risk
“Low” Elevation of Risk
Moderately Elevated Risk
High-Risk
![Page 10: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/10.jpg)
Genetics of Pigmentation & Melanoma: Low Penetrance
• Genome-wide association studies (common, low-penetrance, SNP) – Agouti signaling protein (ASIP, an MSH antagonist) – Tyrosinase (Tyr, key enzyme in melanin synthesis) – Oculocutaneous albinism 2 (OCA2, regulates melanin
synthesis) – Tyrosinase related protein (TYRP1, regulates melanin
synthesis) – SLC45A2 (melanocyte differentiation & pigmentation)
Brown et al., Nat Genet 2008; Bishop et al., Nat Genet 2009
![Page 11: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/11.jpg)
DNA Repair Genes Associated with Melanoma: Low Penetrance
• TERT - Telomerase Reverse Transcriptase
• PARP1 • ATM • CASP8
Barrett JH, Nat Genet, 2011; 43:1108-1113 Bishop DT, Nat Genet, 2009; 41:920-925 MacGregor S, Nat Genet, 2011; 43:1114-1118
![Page 12: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/12.jpg)
≥3 melanomas in a family (any degree of relationship) 12%-41%
≥3 melanomas in an individual 5%-23%
≥3 “cancer events” in a family (any combination of melanoma and pancreatic cancer) ~68%
Which Patients Are Candidates for Genetic Testing: “Rule of Threes”
*Only 1 criteria needs to be met. Consideration should be given to age at diagnosis, UV exposure, skin type, and ethnicity, as there may be exceptions to the “Rule of Threes.”
Leachman et al, JAAD 2009
![Page 13: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/13.jpg)
MC1R: A Gene That Causes Red Hair
Photo courtesy of Rick Sturm, Australia
![Page 14: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/14.jpg)
Effects of MC1R Mutation
• Melanoma risk in the general population • 2-fold increased risk per R allele
• MC1R mutations make CDKN2A mutations worse
• Penetrance in 15 kindreds with CDKN2A mutation was 50% with mean age of onset 58 years • Penetrance was increased to 84% by presence of R allele with a mean age of onset 38 years.
Palmer et al., Am J. Hum. Genet. 2000; Fargnoli et al., JID, 2009; Box et al., Am. J. Hum. Genet. 2001; Hacker et al., JID 2009
![Page 15: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/15.jpg)
Why Test? Exceptional Lifetime Risk!
*Bishop DT, et al. J Natl Cancer Inst 2002;94:894-903. **Rulyak SJ, et al. Cancer 2003;98(4):798-804.
**Parker JF, et al. Arch Dermatol 2003;139:1019-25.
010
20
3040
50
6070
80
Melanoma Pancreatic
MelanomaPancreatic
76%
17%
![Page 16: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/16.jpg)
Can Genetic Testing Improve Compliance with Prevention Behaviors?
![Page 17: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/17.jpg)
Study Design • 2 large p16
mutation families • 3 study groups • Good, balanced
retention • 5 time points • Endpoints:
– Photoprotection – Skin self-exam – Total body
provider exam
Aspinwall et. Al, CEBP, 2013
![Page 18: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/18.jpg)
Photoprotection in Unaffected Carriers (% Time Utilized)
p < 0.024
Genetic testing improved photoprotective behavior in unaffected carriers
![Page 19: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/19.jpg)
TBSEs in the past year at 2 yrs P = 0.0002
P = 0.635
P = 0.032 P = 0.033
% re
porti
ng T
BS
E in
pas
t yea
r
Genetic testing alters compliance with TBSEs
![Page 20: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/20.jpg)
SSE adherence from baseline to 2 yrs
Genetic testing alters compliance with SSEs
![Page 21: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/21.jpg)
What tests are available?
![Page 22: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/22.jpg)
Single Gene Testing for Hereditary Melanoma CDKN2A
Company Price
PreventionGenetics $540
University of Oklahoma $548
GeneDX $660
Center for Human Genetics $675
Emory Genetics $700
Ambry $900
Myriad $900
InVitae $1500
![Page 23: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/23.jpg)
Single Gene Testing for Hereditary Melanoma CDK4
Company Price
PreventionGenetics $680
InVitae $1500 (same price if bundled with CDKN2A, so $750/gene if ordering both)
![Page 24: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/24.jpg)
Panel Testing for Hereditary Melanoma
Company Price Genes
Yale DNA Lab $561 CDKN2A, CDK4
GeneDX $825 CDKN2A, CDK4
Fulgent $1,450 CDKN2A, CDK4, MC1R, BRCA1&2 + 8 others
Myriad $4,040 CDKN2A, CDK4, BRCA1&2 + 21 others
Ambry 4,250 CDKN2A, CDK4, BRCA1&2 +24 others
![Page 25: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/25.jpg)
Example Panel Report - Positive
![Page 26: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/26.jpg)
Example Panel Report - Negative
![Page 27: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/27.jpg)
Current Status of Direct to Consumer Genetic Testing
![Page 28: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/28.jpg)
Increasing Public Awareness: Google Trends
“23andMe”
“BRCA”
Angeline Jolie double mastectomy
FDA instructs 23andMe to stop selling tests
![Page 29: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/29.jpg)
Reactions to New Technology: Utopian
![Page 30: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/30.jpg)
Reactions to New Technology: Utopian
![Page 31: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/31.jpg)
Reactions to New Technology: Terror
![Page 32: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/32.jpg)
Reactions to New Technology: Terror
![Page 33: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/33.jpg)
Rapidly Evolving Landscape
2011 2013
![Page 34: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/34.jpg)
Current Landscape Company Price What Tested? Results to? Counseling?
23andMe* $99 SNPs Consumer Yes/No (Informed DNA)
DNA DTC $900 $7,000
Exome @ 80x Genome @ 30x
Consumer, raw data
No
Genetic Testing Laboratories
$315 SNPs MD Yes
Pathway Genomics
$399 SNPs MD Yes
Counsyl
$600 $1,000
SNPs via PCR SNPs via exon seq
MD Yes
*Not currently offering tests
![Page 35: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/35.jpg)
Timeline of a Landmark Year: 2010
• Beginning of Myriad litigation culminating in Supreme Court decision in 2013 against Myriad stating that a “DNA segment is a product of nature and not patent-eligible merely because it has been isolated”
• FDA warns genetic companies doing DTC testing that tests will be considered medical devices
• Two companies, deCODEme and Navigenics, stop sales and are acquired by other companies in 2012
• Other companies (Counsyl, Pathways) quickly end DTC sales
![Page 36: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/36.jpg)
23andMe and the FDA • Saliva sample ‘spit kits’ submitted for SNP
genotyping • Time magazine ‘Invention of the Year’ 2008 • 650,000 tests to date • Affiliation with Google and access to ‘big data’ • FDA’s 2010 take: medical devices, have not
been analytically or clinically validated • November 2013: FDA stops sales of 23andMe
kits • Two class-action lawsuits pending for
“misleading advertising”
![Page 37: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/37.jpg)
Summary
• When to test: Rule of threes
• Available genetic tests for melanoma: Single gene and panel tests available
• Current status of DTC genetic testing: Controlled
![Page 38: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/38.jpg)
Future Questions
• What is the future for direct-to-consumer genetic testing? Is there one? Should there be one?
• Should DTC testing be considered a medical device, or something else?
• What will the real legacy of this new, powerful technology become?
![Page 39: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/39.jpg)
Acknowledgements
• Matthew Majerus, M.D. – OHSU Dermatology Resident, PGY-2
![Page 40: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/40.jpg)
Intra-tumoral Immunotherapy of Melanoma: What happens in there, does not always stay there!
Shailender Bhatia, MD
Assistant Professor, Medical Oncology Department of Medicine UW / SCCA / FHCRC
![Page 41: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/41.jpg)
Intra-tumoral Immunotherapy: What happens in there,
does not always stay there
Shailender Bhatia, MD University Of Washington
![Page 42: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/42.jpg)
1. Establish goals of care • Durable disease-control (CURE) • Prolong lifespan • Preserve/improve Quality-of-life
2. Match desired goals to the safety/efficacy characteristics of the therapy
• Rate of tumor shrinkage or clinical benefit • Kinetics of response (rapid vs delayed) • Duration of response • Side-effects • ?Cost
Systemic therapy is the mainstay of therapy for metastatic disease
![Page 43: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/43.jpg)
Until 2011, few standard therapy options existed.
Treatment of Metastatic Melanoma: An Overview Bhatia S et al. ONCOLOGY. 2009; 23:6; 488-500
US-FDA approved therapies for metastatic melanoma. Dacarbazine (1975) No proven OS benefit High-dose IL-2 (1998)
![Page 44: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/44.jpg)
Cancer Immunotherapy Works (Albeit only in a small subset of melanoma patients)
Response
ORR ~16%
CR 6%
Majority of CR’s are durable.
Likely CURED
Toxicity is substantial
Retrospective Analysis of 270 patients treated at the NCI by High-Dose IL-2
[Atkins, MB et al. JCO (1999)]
![Page 45: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/45.jpg)
Hodi FS et al. NEJM. 2010
2010: The ceiling was finally broken
![Page 46: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/46.jpg)
Ipilimumab: An Example of Response
Maggon et al, 2011
![Page 47: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/47.jpg)
However, responses are infrequent, and complete remissions (CR) rare.
![Page 48: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/48.jpg)
Adverse Events from Ipilimumab
[Hodi FS et al. NEJM. 2010]
Immune-related AE Any grade (%)
Grade 3 or higher (%)
Any IrAE 60 15 Dermatologic (pruritus, rash, vitiligo)
43 2
GI (Diarrhea, colitis) 29 8 Endocrine (Hypophysitis, hypothyroidism, adrenal insufficiency)
8 2
Hepatic 4 0 Others 5 2
![Page 49: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/49.jpg)
True impact of Ipilimumab’s success story goes far beyond Melanoma
[Topalian S et al. NEJM. 2012; Brahmer J et al. NEJM. 2012]
![Page 50: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/50.jpg)
[Wolchok J et al. NEJM. 2013]
![Page 51: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/51.jpg)
Near-CRs seen in a large proportion of pts
ORR 40% N=47; All dose levels included
[Wolchok J et al. NEJM. 2013]
![Page 52: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/52.jpg)
Toxicities can be a problem though
• Grade 3/4 treatment-related AEs: 53% – Elevations in Lipase (13%), AST (13%, ALT (11%)
• Cohort 3 (Nivo 3 + Ipi 3) deemed to have unacceptable
level of toxicity – 3/6 patients had Gr 3 or 4 lipase elevations lasting
more than 3 weeks.
[Wolchok J et al. NEJM. 2013]
![Page 53: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/53.jpg)
Why does immunotherapy not work all the time?
[Weiner L NEJM 2008 ]
![Page 54: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/54.jpg)
Intra-tumoral Immunotherapy
53
• Takes the action into the heart of the tumor, where it is needed
• May have a better chance of overcoming local immune evasion mechanisms.
• Avoid systemic toxicity
![Page 55: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/55.jpg)
Systemic versus Local Immunotherapy
SYSTEMIC
Potential for ‘Global’ responses in what is essentially a ‘systemic’ disease. Systemic toxicities - Overkill for solitary or oligo-metastatic disease.
? Adequate intratumoral drug levels – limited dose-escalation due to systemic side-effects. – penetration into the tumor microenvironment.
LOCAL
Mostly local toxicities
? Feasibility – dependent upon location of the lesions (superficial versus deep; critical organs)
? Decreased potential for ‘global’ responses
![Page 56: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/56.jpg)
Several potential advantages to intratumoral immunotherapy
• Improve the risk:benefit ratio of otherwise-toxic drugs.
• Stimulate immune responses against diverse (including unknown) tumor antigens.
• May overcome the hostile immune-suppressive tumor microenvironment (TME)
But, can the local benefits spill over into the
systemic circulation?
![Page 57: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/57.jpg)
Scientific hypothesis: What happens there, does not always stay there.
![Page 58: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/58.jpg)
How to assess systemic immune responses from local immunotherapy?
• Regression of distant non-injected lesions. - Preferably in a different organ type (e.g. visceral tumor regression from injection of cutaneous tumors)
• Prolonged stable disease or progression-free
interval.
• Anti-tumor immune responses in peripheral blood.
![Page 59: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/59.jpg)
Intratumoral Injection of IL-12 plasmid followed by in vivo Electroporation
![Page 60: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/60.jpg)
Interleukin-12 (IL-12)
• Powerful immune stimulant
• Anti-cancer efficacy seen in early clinical trials
• However, systemic administration of IL-12 was
associated with severe toxicities. - GI, Liver toxicity - Death.
![Page 61: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/61.jpg)
Adil Daud, MD UCSF
[Daud A et al. J Clin Oncol 2008]
![Page 62: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/62.jpg)
Treatment led to Increased Intratumoral Expression of IL-12 protein
(for up to 5 weeks after only 3 injections on days 1,5, 8)
[Daud A et al. J Clin Oncol 2008]
![Page 63: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/63.jpg)
Clinical Efficacy
Distant responses in 4/19 patients – 3 CRs Disease Control Rate = 10/19 or 53%
[Daud A et al. J Clin Oncol 2008]
![Page 64: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/64.jpg)
[Daud A et al. J Clin Oncol 2008]
Development of Vitiligo
![Page 65: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/65.jpg)
Phase 2 Study of IL-12 EP in patients with
Merkel Cell Cancer And
Melanoma
![Page 66: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/66.jpg)
• IL-12 EP is delivered on days 1, 5 and 8 of each cycle.
• Maximum of 4 tumors (or treatment zones) are treated in each cycle; different set of tumors can be picked for a new cycle.
• The total daily dose of IL-12 plasmid is 1 mg in 2 mL (0.5
mg/mL); 0.25 mg per each treatment zone.
Study Methods (Contd)
![Page 67: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/67.jpg)
The EP applicator (OncoSec Medical Inc) delivers six pulses at a field strength (E+) of 1300 V/cm and pulse width of 100 µs.
Study Methods (Contd)
![Page 68: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/68.jpg)
Then the show begins.
![Page 69: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/69.jpg)
Increased Intra-tumoral IL-12 protein expression
• 3 patients have paired baseline and post-treatment (week 3) tumor IL-12 protein levels available (as measured by a validated ELISA). – The IL-12 protein level is
increased [25-1000 fold] post-treatment in 3/3 (100%) patients’ biopsy samples [Figure].
Figure: Increased IL-12 protein expression in post-treatment versus baseline tumor biopsy in 3/3 patients.
[Bhatia S et al. SITC poster. 2012]
![Page 70: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/70.jpg)
Impressive response in some patients
Pre-treatment Post-treatment (Day 270)
![Page 71: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/71.jpg)
Intriguing evidence of systemic immune response in another patient
Post-treatment (Day 25)
![Page 72: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/72.jpg)
Therapy has been tolerated well with mostly mild local side effects.
Most common treatment-related AE is transient (lasting ~ 3 seconds) pain associated with electroporation.
– No systemic side-effects (such as flu-like symptoms) have been noted in any patients so far.
[Bhatia S et al. SITC poster. 2012]
![Page 73: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/73.jpg)
002: C2 Wk2 002: C2 Wk6
Mild injection-site discoloration has been noted in some patients.
[Bhatia S et al. SITC poster. 2012]
![Page 74: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/74.jpg)
W420 TIL samples
IFNg response by W420 TIL in presence MCPyV CT44-52 peptide
Oct’11 Jan’12 Feb’12 Sep’12 Oct-Nov’12
No IFNg response by W420 TIL in presence of ST83-91 peptide IFNg response by W420 TIL in presence of ST83-91 peptide
Patient 002: Suggestion of epitope
spreading
![Page 75: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/75.jpg)
IT CD8+ Infiltration (prelim)
Figure: There appears to be increased CD8+ infiltration into the tumors after therapy (patient 005).
In 1/2 patients, there appears to be increased CD8+ infiltration into the tumors; rest had insufficient tumor tissue for comparison.
![Page 76: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/76.jpg)
Summary
• Local delivery of IL-12 is feasible via intratumoral injection of IL-12 plasmid DNA followed by in vivo EP.
• Treatment is tolerated well overall, with transient
grade 1 pain associated with EP.
• No systemic treatment-related AEs occurred so far.
• Preliminary evidence of efficacy has been noted with regression of injected as well as non-injected tumors in some (but not all) patients.
![Page 77: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/77.jpg)
Intratumoral Immunotherapy of skin cancers at SCCA.
A phase 2 study of pIL-12 EP in patients with MCC. {PI: Bhatia} A phase 2 study of pIL-12 EP in patients with Melanoma. {PI: Adil Daud, UCSF} A proof-of-concept trial of intratumoral GLA (synthetic TLR-4 agonist) in MCC. {PI: Bhatia} Single 8-Gy Radiation therapy of MCC tumors. {Led by: Parvathaneni}
![Page 78: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/78.jpg)
OncoVEXGMCSF in melanoma (Oncoloytic HSV-1 expressing GM-CSF)
Talimogene laherparepvec (T-VEC)
![Page 79: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/79.jpg)
Phase 2 results with OncoVEXGMCSF
[Senzer NN. JCO 2009]
![Page 80: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/80.jpg)
Disease may be too aggressive for immunotherapy in some patients
003 C1 D1
Pt 003 (SM) - Recurrent MCC – 4 zones treated – PD after 1 cycle – responded nicely to salvage RT
003 C1 D29
![Page 81: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/81.jpg)
0 50 100 150 200 250 300 350 400
Days from diagnosis
Response to therapy or stable disease on the CT scan
Progressive disease on the CT scan
41BB (164 dys without PD)
W787, 56 yo woman (nurse), 7 cycles of 41BB at 0.12 mg/kg
XRT XRT
Combining local with systemic immunotherapy
![Page 82: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/82.jpg)
Combining local with systemic immunotherapy
![Page 83: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/83.jpg)
Conclusions
• Local intratumoral immunotherapy can result in clinically meaningful systemic immune responses.
• Toxicity is generally favorable with mostly local AEs.
• Combination of local and systemic immunotherapy
approaches may overcome some limitations of either approach and deserve further investigation.
What happens in Vegas, does not always stay in Vegas!
![Page 84: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/84.jpg)
Acknowledgments
Patients/Families
Kim Margolin John Thompson Paul Nghiem
Clinicians Scott Tykodi Upendra Parvathaneni David Byrd Sylvia Lee Aude Chapuis
Clinical Support Staff Jeanette Hammond, PA RNs (Jon, Debbie, Christine, Sharon) Marla Teeny (TC)
Research Support Staff Nichole Real (RC) RCs (Cassie Oh, Mike Donahue) Phase 1 team Sandy Bergevin, Sarah P
Nghiem Lab
Adil Daud, Rich Heller, OncoSec
![Page 85: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/85.jpg)
Kauai, here I come!!
![Page 86: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/86.jpg)
Morning Break
10:10 – 10:25 am
![Page 87: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/87.jpg)
Radiotherapy and Immune Therapy: An alliance for the future
Upendra Parvathaneni, MD
Assistant Professor, Radiation Oncology University of Washington School of Medicine
Radiation Oncologist, Seattle Cancer Care Alliance
![Page 88: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/88.jpg)
Radiotherapy and Immunotherapy : an alliance for the future
Upendra Parvathaneni Radiation Oncologist, University of Washington
April 2014
![Page 89: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/89.jpg)
disclosures
• none
![Page 90: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/90.jpg)
Objectives
• Brief introduction to radiotherapy (RT) in melanoma
• Observations of systemic/immunologic effects of RT
• RT interaction with immunotherapy – the new frontier
• Modern RT tools to target tumors
![Page 91: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/91.jpg)
RT effects on melanoma
![Page 92: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/92.jpg)
Traditional role of RT in melanoma
• Post operative treatment of “high risk” node positive patients
• To prevent local cancer relapse within the treated field
• RT was fractionated over 3-6 weeks to allow normal structures to repair between treatments
• RT for palliation of metastases
![Page 93: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/93.jpg)
![Page 94: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/94.jpg)
Palliative RT for melanoma
![Page 95: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/95.jpg)
Dose = energy absorbed in tissues at a specified depth Units : Gray (100 cGy)
Megavoltage linear accelerator
![Page 96: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/96.jpg)
Major types of RT & physical properties
• Photons/Xrays
• Electrons
Depth in tissue
absorbed dose
Depth in tissue
absorbed
dose
![Page 97: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/97.jpg)
RT target = DNA
• maximum effect on dividing cells that rely on intact DNA during cell division
• Hence, tumors with dividing cells responded to RT
• Normal cells are relatively spared, if allowed to repair
![Page 98: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/98.jpg)
Immune system is needed to fight cancer
![Page 99: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/99.jpg)
Immunotherapy in Melanoma
• Interferon 2a • Interleukin -2 • CTLA 4 blockade (ipilumimab) • Anti PD -1 therapy • Therapeutic vaccines
![Page 100: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/100.jpg)
Systemic/Immunological effects of RT – the new biology
Demaria et al. IJROBP. 2005;63(3):655-66.
![Page 101: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/101.jpg)
Immunological effects of RT in melanoma
• Animal modals – eg fewer lung mets in mice that had RT (25 Gy) to melanoma vs no RT b4 surgery. Perez et al Int J Radiat Biol 2009;85:1126-36
• Clinical data :
- abscopal effects - vitiligo effects
![Page 102: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/102.jpg)
Abscopal effects of RT
• ab = away from (latin) scopus = target, aim (greek)
• Abscopal effect is a phenomenon where localized irradiation of a tumor causes not only a shrinking of the irradiated tumor but also a shrinking of tumors far from the irradiated area.
![Page 103: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/103.jpg)
Abscopal effects of RT
• Described in melanoma, renal cell ca, lymphomas, merkel cell ca, etc…
• First reported in a case of melanoma in 1975 - treatment with neutrons (14.4 Gy) to groin nodes regressed pelvic and para aortic lymph nodes. Kingsley DP Br J Radiology 1975;48:863-66
![Page 104: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/104.jpg)
Abscopal effects of RT
![Page 105: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/105.jpg)
Abscopal effects of RT +
ipilumimab
N Engl J Med 2012;366:925-31.
RT: 28.5 Gy in 3 fx
Regression of untreated mass in hilum of lung Regression of Untreated masses in liver and spleen
![Page 106: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/106.jpg)
RT = 27 Gy in 3 # 3 and 6 months post RT
Abscopal effects RT + ipilumimab
![Page 107: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/107.jpg)
Immunological effects of RT in melanoma
Note - depigmentation “vitiligo” effect : sign of effective immunotherapy Vitiligo in non irradiated sites noted in some cases
![Page 108: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/108.jpg)
Halo depigmentation – an immunologic effect of RT note : around treated lesions
compared with RT skin reaction in the rest of the field
![Page 109: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/109.jpg)
RT + high dose IL2 immunotherapy
• Pilot study of 7 pts with metastatic melanoma • 1-3 doses of RT (20-60Gy) + high dose IL-2 • 71% achieved a response - 1 CR and 4 PR • Median duration of response = 553 days • Much higher than historically expected
response rates (10-15%)
www.ScienceTranslationalMedicine.org 6 June 2012 Vol 4 Issue 137
![Page 110: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/110.jpg)
Discordant effects of RT
• Systemic RT – total body irradiation = immune suppressive - used to suppress host immunity against foreign graft during allogeneic bone marrow transplantation
• Local RT = immune stimulatory
• High dose per fraction reqd for immune
stimulatory effects - possible only with newer techniques
![Page 111: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/111.jpg)
Developments in RT technology allow for the use of
high-dose ablative RT (8-20 Gy) to target tumors
with limited damage to the surrounding normal tissue
![Page 112: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/112.jpg)
Historical RT = crude techniques accurate BUT morbid
![Page 113: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/113.jpg)
Technological advances : IMRT
multiple beam angles
parts of target are treated by “segments” of a beam
intensity map of each field conforms with target in 3 dimensions
IMRT = highly conformal steep dose gradients
![Page 114: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/114.jpg)
Proton RT at UW Feb 2013
![Page 115: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/115.jpg)
Proton RT at UW Feb 2013
![Page 116: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/116.jpg)
protons vs photons
![Page 117: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/117.jpg)
![Page 118: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/118.jpg)
Our 1st H&N proton patient
![Page 119: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/119.jpg)
Optic chiasm sparing treatment
![Page 120: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/120.jpg)
RT available at UW
• Conventional RT with conformal techniques: IMRT, SBRT
• Gamma knife • Protons
• Neutrons
![Page 121: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/121.jpg)
Thank you
![Page 122: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/122.jpg)
Questions & Answers with Morning Presenters
Dr. Sancy Leachman
Dr. Shailender Bhatia
Dr. Upendra Parvathaneni
![Page 123: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/123.jpg)
Lunch & Networking
11:30 am – 12:30 pm
![Page 124: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/124.jpg)
Personalized and Precision Medicine in Cancer Care
David Byrd, MD Director of Surgery, Seattle Cancer Care Alliance
Co-Chair, Northwest Melanoma Symposium
![Page 125: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/125.jpg)
Personalized and Precision Medicine in
Cancer Care David R Byrd, MD
Director of Surgical Oncology SCCA
Professor, Department of Surgery University of Washington
![Page 126: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/126.jpg)
IOM Report Sept 10, 2013 Delivering High-Quality Cancer Care:
Charting a New Course for a System in Crisis
• Crisis is due to: – Growing demand for cancer care:
• In U.S. 14M have had cancer • 1.6M new diagnoses/year
– By 2030, expect 2.3M new diagnoses/year
• By 2022, expect 18M cancer survivors – Increasing complexity of treatment – Shrinking workforce – Rising costs
www.iom.edu/qualitycancercare
![Page 127: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/127.jpg)
Personalized Medicine - covers the entire continuum of
quality cancer care Tesla
![Page 128: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/128.jpg)
Diagnosis and Staging of Cancer
• Histology • Immunohistochemistry • Molecular diagnostics:
– Genomics of tumor – Pharmacogenomics – Other omics
![Page 129: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/129.jpg)
Histologic Diagnosis and Cancer Staging (TNM)
• Primary tumor organ of origin – Breast, colon, etc. = T
• Spread to regional lymph nodes = N • Spread to distant sites/organs = M
![Page 130: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/130.jpg)
Melanoma (Tissue level)
Normal skin melanoma
Primary tumor thickness– 1.2 mm, ulcerated: (T2b)
![Page 131: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/131.jpg)
Lymph node metastasis – N1
Lymphocytes
melanoma cells
![Page 132: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/132.jpg)
Metastasis to bone - M1
![Page 133: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/133.jpg)
Pathologic Staging T2b N1 M1 – Stage IV Provides clinicians and patients with: - size/local invasion of primary - extent of spread of disease - prognostic information
![Page 134: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/134.jpg)
Melanoma Survival Curves by Stage
Sur
viva
l Rat
e
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Survival Time in Years
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0
Stage I (n=18,370)
Stage II (n=9,269)
Stage III (n=3,307)
Stage IV (n=7,972)
AJCC Cancer Staging Manual, 7th ed, 2009
![Page 135: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/135.jpg)
Dr. Michael Kattan
Chairman of Quantitative Health Sciences, Cleveland Clinic
![Page 136: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/136.jpg)
![Page 137: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/137.jpg)
-Apply molecular diagnostics -Deliver targeted therapy to actionable mutations in tumor
Precision Medicine
![Page 138: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/138.jpg)
The Promise of Precision Medicine in Cancer Care
Morphologic diagnosis and phenotypic tumor classification Generic therapeutic regimens with unpredictable effectiveness Treatments with unpredictable adverse effects on patients
Molecular characterization of tumors and pathways Targeted therapies tailored to the molecular profile of the disease Drug regimens planned around host genetics that portend toxicity
Advances in Molecular Technologies and Research
Understanding Molecular Biology of Host and Disease
Empiric – population-based Precision Medicine
Courtesy of Dr. Carolyn Compton
![Page 139: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/139.jpg)
Precision Medicine Issues
• Technology – evolving rapidly • Genetic and molecular diagnostics • Effectiveness of targeted treatment • Affordability/Costs • Ethics • Prevention
![Page 140: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/140.jpg)
Personalized Medicine: Replacing Trial and Error Medicine
Reproduced with Permission from the Personalized Medicine Coalition.
![Page 141: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/141.jpg)
Personalized Medicine: Replacing Trial and Error Medicine
Reproduced with Permission from the Personalized Medicine Coalition.
![Page 142: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/142.jpg)
Immunohistochemistry IHC – Melanoma (Cell level)
![Page 143: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/143.jpg)
Precision Medicine What’s Under the Hood?
![Page 144: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/144.jpg)
Genetic Mutations in Cancer
• Germline mutations: – Present at birth – Present in all cells – Can identify predisposition to cancer(s)
• Somatic mutations: – Acquired during life – Found in tumors in abundance – Can be exploited as specific targets for
treatment of cancers
![Page 145: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/145.jpg)
BROCA Comprehensive Cancer Panel (Germline Genetic Testing)
![Page 146: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/146.jpg)
Disclosure of Genetic Testing Results
• Genetic Counseling up front • Panels of genes may identify other
consequential mutations – Should the patient be informed of all the
information that will be obtained? – Who “owns” the management of unintended
genetic results? • The ethics have not been worked out!
Lolkema et al JCO, 2013
![Page 147: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/147.jpg)
Somatic Mutations Schema of Precision Medicine
MacConaill L E , Garraway L A JCO 2010;28:5219-5228
©2010 by American Society of Clinical Oncology
![Page 148: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/148.jpg)
Genetic and Molecular Diagnostics (Intracellular)
• Sequencing of segments of DNA coding for mutated proteins – e.g. EGFR, KRAS, BRAF, ALK
• Gene Panel testing of known or suspected mutations – UW: OncoplexTM
• Whole exom DNA sequencing
![Page 149: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/149.jpg)
![Page 150: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/150.jpg)
Exemplary Oncoproteins and Targeted Cancer Pathways
Cell surface membrane
DNA
Garraway, et al. JCO 31:1806-1814, 2013
Cell signaling
![Page 151: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/151.jpg)
Exemplary Oncoproteins and Targeted Cancer Pathways
Cell surface membrane
DNA
Garraway, et al. JCO 31:1806-1814, 2013
Cell signaling
Therapeutic targets In lung carcinoma
![Page 152: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/152.jpg)
Exemplary Oncoproteins and Targeted Cancer Pathways
Cell surface membrane
DNA
Garraway, et al. JCO 31:1806-1814, 2013
Cell signaling
Therapeutic target in melanoma
![Page 153: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/153.jpg)
Exemplary Oncoproteins and Targeted Cancer Pathways
Cell surface membrane
DNA
Garraway, et al. JCO 31:1806-1814, 2013
Cell signaling
Therapeutic target in hereditary breast CA
![Page 154: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/154.jpg)
Colin Pritchard, UW Lab Medicine
Tier 1: Currently Actionable
ABL1 ALK BCR BCL2L11 BRAF RET CDK4 CEBPA KIF5B DDR2 EML4 EGFR ERBB2 FLT3 IDH1 IDH2 JAK2 RARA
KIT KRAS MPL NPM1 NF2 NRAS PDGFRA PML RICTOR ROS1 TSC1 TSC2
Tier 2: Actionable in the Near Future
ABL2 AKT1 AKT2 AKT3 ASXL1 ATM AURKA AURKB BAP1 BCOR CBL CBLB CDK6 CDK8 CHEK1 CHEK2 DNMT3A EPHB2 ERBB3 ERBB4 FGFR1 FGFR2 FGFR4 FLT1 FLT4 GATA2 GNA11 GNAQ GRM3 HDAC4 HIF1A HRAS IGF1R JAK3 KDM6A KDR
MAP2K1 MAP2K2 MAPK1 MC1R MCL1 MEN1 MET MLH1 MLL MRE11A MSH2 MSH6 MYC MYCN NOTCH1 PAX5 PDGFRB PIK3CA PIK3R1 PMS2 PTEN RAF1 NKX2-1 SMO SRSF2 SUZ12 TET2
TYR VHL MITF ERCC2
Tier 3: Frequently Mutated
APC BAK1 BCL2 CCND1 CCNE1 CDH1 CDKN2A CREBBP CRLF2 CSF1R CTNNB1 EPHA3 EPHA5 EPHB6 ETV6 EZH2 FBXW7 FGFR3 GAB2 GATA1 GNAS GRIN2A HNF1A IKZF1 IL7R JAK1 MAP2K4 MDM2 MDM4 MUTYH MYCL1 NF1 STK11 NOTCH2 PBRM1 PRPF40B PTCH1 PTPN11 PTPRD RB1 RPS14 RUNX1 SF1 SF3B1 SMAD2 SMAD3 SMAD4 SMARCA4 SMARCB1 SPRY4 SRC TFG TGFBR2 TP53 TRRAP U2AF1 U2AF65 WT1 ZRSR2
Germline Pharmacogenomics
ABCB1 ABCC2 ABCC4 ABCG2 C1orf144 COMT CYP1B1 CYP2C19 CYP2C8 CYP2D6 CYP3A4 CYP3A5 DPYD EIF3A ESR1 ESR2 FCGR1A UMPS FCGR2A FCGR3A GSTP1 GUCY1A2 ITPA LRP2 MAN1B1 MTHFR NQO1
NRP2 SLC19A1 SLC22A2 SLCO1B3 SOD2 SULT1A1 TPMT TYMS UGT1A1
UW-OncoPlex™ v2
Genes Targeted: 194 DNA Sequenced: >850,000 bp
>500X Coverage
![Page 155: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/155.jpg)
![Page 156: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/156.jpg)
Next Generation Whole Exom DNA Sequencing
• Technology is here now • Costs are expensive but plummeting • Time to interpret results is long but
decreasing • The volume of data generated is vast,
especially over time • Emerging field of computational
biology
![Page 157: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/157.jpg)
Treatment for Metastatic Melanoma 1980’s to 2011
• Node positive melanoma – alpha interferon only FDA-approved additional treatment
• Metastatic (distant sites) melanoma – DTIC (chemo) or Interleukin-2
• Clinical trials
![Page 158: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/158.jpg)
Targeted Pathways in Melanoma
Fecher, et al JCO 25:1606, 2007
![Page 159: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/159.jpg)
Modeling of Information Flow in Biological
Networks
Targeted Therapeutics and Cancer: Harder Than We Thought
Molecular Subtyping and
ID of RX Targets
Rx-Resistance via
Redundant Molecular Pathways
Initial Rx-Response to
Targeted Rx
B = 15 weeks Rx (Zelboraf®) C = 23 weeks Rx and emergence of MEK1C1215 mutant Wagle et al. (2011) JCO 29, 3085)
Courtesy of Dr. Carolyn Compton - AJCC
![Page 160: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/160.jpg)
Emerging Immune and Molecular Strategies/Therapies in Melanoma • Targeted therapies:
– Mutated BRAF inhibitors – vemurafenib, dabrafenib
– C-kit inhibitors – Imatinib (Gleevec) – MEK inhibitors – trametinib
• Immunotherapy – immune checkpoint blockers: – Ipilimumab (Yervoy) - anti-CTLA-4 antibody – Anti –PD-1 – Nivolumab, Lambrolizumab
![Page 161: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/161.jpg)
Pre-Rx
Post-Rx
Immunotherapy for Melanoma
![Page 162: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/162.jpg)
The Path Forward
![Page 163: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/163.jpg)
The Problem
“…there are known knowns; there are things we know we know. We also know there are known unknowns; that is to say we know there are some things we do not know. But there are also unknown unknowns -- the ones we don't know we don't know." --Donald Rumsfeld
http://www.youtube.com/watch?v=GiPe1OiKQuk
Slide courtesy of Dr. Richard Schilsky
![Page 164: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/164.jpg)
What Do We Know?
• Targeted therapy makes clinical sense and is available now for some cancers
• Targeted therapy doesn’t always work or effectiveness is short-lived
• Tumors evolve in the patient, spontaneously and under selection pressure
• Costs of testing and targeted treatment must be addressed up front.
• Resurgence of promise for immunotherapy
![Page 165: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/165.jpg)
What Don’t We Know? • How to optimally combine agents (dose,
schedule, sequence) • How to efficiently integrate data sets • How to quickly convert a lab assay to a clinical
test • How to navigate regulatory mazes • How to convey test results to physicians in a
useful format • How to define how individual tumors behave • How to present the economic case for targeted
therapy
Courtesy of Dr. Richard Schilsky
![Page 166: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/166.jpg)
Costs of Genetic Sequencing
We are rapidly approaching availability of the $1,000 genome
![Page 167: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/167.jpg)
![Page 168: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/168.jpg)
The Patient of the Past
![Page 169: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/169.jpg)
The Patient of the Future
DNA Sequence Barcode on
forehead
Doctor, what do we do about this?
![Page 170: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/170.jpg)
“You want the Truth? You can’t handle the Truth.”
Jack Nicholson - A few Good Men
![Page 171: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/171.jpg)
Linear Growth
Exponential Growth
Technology
Clinical Care
Gap
Rat
e of
Impr
ovem
ent
Doing One’s Best: 2013
![Page 172: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/172.jpg)
![Page 173: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/173.jpg)
Thank you!
![Page 174: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/174.jpg)
Patient Panel
1:00 – 2:45 pm
![Page 175: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/175.jpg)
Afternoon Break
Enjoy healthy smoothie samples from SCCA Nutrition in the Great Hall!
2:45 – 3:15 pm
![Page 176: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/176.jpg)
Getting Involved
Tim Turnham, PhD Executive Director
Melanoma Research Foundation
![Page 177: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/177.jpg)
Getting Involved
April 5, 2014
![Page 178: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/178.jpg)
Tell Your Story
181
Melanoma is not widely recognized.
Oh, my friend had that. No, wait it was lymphoma, or was it mesothelioma, no maybe multiple myeloma….
Melanoma? That’s just skin cancer, right?
The consequence is a cavalier attitude toward risk, toward early detection, and even around treatment.
![Page 179: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/179.jpg)
Tell Your Story: Primary Prevention
182
UV Radiation is a factor in the majority of cutaneous melanomas (maybe as high as 75%) in the United States. •Tanning salons
– More numerous than Starbucks/MacDonalds – Largely unregulated: bulb intensity, frequency of use, etc. – Often uses misleading marketing
•Culture of tanning – “Healthy glow” – Beauty/fashion/celebrity industries are selling a lie
![Page 180: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/180.jpg)
Tell Your Story: Secondary Prevention
183
Early detection is key!
![Page 181: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/181.jpg)
Tell Your Story: Patient Education
184
What about the patient in North Dakota who doesn’t look for information on the internet, won’t travel for care, and whose oncologist sees one or two melanomas a year?
– # of patients in clinical trials – # of patients treated with Dacarbazine/chemo
CME and general marketing won’t work; key is peer-to-peer communication.
![Page 182: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/182.jpg)
Share Your Strength
185
MRF education and volunteer efforts are built on the absolute conviction that patients who are well informed and well supported live longer and better
• Support Groups •MPIP • Phone Buddies
![Page 183: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/183.jpg)
Become a Lobbyist!
186
•Ongoing “asks” – Tanning legislation—federal and state – CDMRP – NIH/CDC
•Emerging Issues – Oral Parity – Specialty Tiering – Pricing policies (per mg)
•How to get started – MRF Hill Day – Virtual Advocacy Program
![Page 184: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/184.jpg)
Invest In Better Solutions
•Miles for Melanoma •Host a fundraiser •Write a check •Consider an estate gift
187
![Page 185: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/185.jpg)
Do Something!
Commit to doing two things in the next year: • Send an email to your member of Congress • Hold a dinner party and tell your story • Contact local media • Run in a Miles for Melanoma event • Speak at a school group • Write a check to some melanoma effort • Sign up to volunteer • Make at least one post on MPIP • Take patient or caregiver brochures to your dermatologist/oncologist • Create a fundraising event • Participate in a clinical trial • Become a Phone Buddy
188
![Page 186: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/186.jpg)
Together we can change the world!
189
Step by step the longest march Can be won, can be won.
Many stones to build an arch; Singly none, singly none.
And by union what we will, can be accomplished still.
Drops of water turn the wheel sing we on, sing we on.
![Page 187: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/187.jpg)
![Page 188: 2014 Northwest Melanoma Symposium Slide Deck](https://reader035.vdocuments.us/reader035/viewer/2022062512/5541f57f550346cf068b45c3/html5/thumbnails/188.jpg)
Thank you for joining us at the 2014 Melanoma Symposium!
(Video footage of the symposium will be available at the end of April at www.sccablog.org.)